Lifestyle choices of the present generation have changed drastically from the previous one, spurring severe consequences and health hazards. Increasing
cases of cancer registered around the world is one such consequence that is raising alarm globally. Of the various kinds of cancer, colorectal cancer is among the more common ones.
This type of cancer is identified by abnormal cell growth in the inner walls of the large intestine. Many a time, hereditary factors play a very important
role in determining the chances of a person developing colorectal cancer. It is a fatal disease, owing to which a majority of the research is dedicated to
discovering drugs to cease the abnormal cell growth to increase the patient’s lifespan. Apart from lifestyle choices, the common tendency among people to
postpone tests, diagnosis, and subsequent treatment is the key factor responsible for the increasing number of patients diagnosed with colorectal cancer
Colorectal Cancer Drugs to Register High Demand Owing to Low Severity of Side-Effects
Cancer researchers of modern times are more aware about the genetic changes that occur at the onset of this fatal disease. As a result, the drugs and
treatment procedures that researchers and scientists are coming up with these days focus more on addressing such fundamental causes rather than the easily
visible symptoms of the disease. These drugs and treatment procedures fall within the ambit of the colorectal cancer therapeutics market.
When compared to other standard drugs administered during chemotherapy, drugs used for the treatment of colorectal cancer work in a completely different
way. One of the major benefits of colorectal cancer drugs is that they have different, less intense side effects than drugs used for other cancers. These
drugs can be either administered to the patients independently or in combination with other drugs.
CYRAMZA, CPP-1X, Xilonix, MelCancerVac, Lonsurf, TS-1/Teysuno, and Nintedanib are the most common drugs used in colorectal cancer therapeutics.
Impressive Healthcare Facilities makes North America the Largest Regional Colorectal Cancer Therapeutics Market
Geographically, the market for colorectal cancer therapeutics can be segmented into Europe, Asia Pacific, North America, and Rest of the World. Of these,
North America leads the global colorectal cancer therapeutics market, owing to the greater number of colorectal cancer cases registered in the region. In
addition, the overall healthcare facility scenario in North America is highly developed. It has adequate infrastructure and the population is aware of the
treatment and diagnosis options for colorectal cancer, which has positively impacted the colorectal cancer therapeutics market in the region. Fluorouracil
and Capecitabine are two of the most commonly used chemotherapy drugs in North America used during the treatment of colorectal cancer.
Asia Pacific is expected to emerge as the fastest growing regional market for colorectal cancer therapeutics in the next few years. Escalating population
density together with rising incidence of colorectal cancer in China and India is likely to drive the colorectal cancer therapeutics market in the region.
However, unwillingness of the regional population to adopt the new school of drugs and inadequate awareness pertaining to the treatment and diagnosis of
the fatal disease will inhibit the colorectal cancer therapeutics market growth in the region to an extent.
Of the leading companies in the global colorectal cancer therapeutics market, Pfizer and Eli Lilly have recently collaborated to continue clinical research
on Tanezumab (a drug used as cancer painkiller). To continue its research on the drugs, Pfizer is likely to receive US$200 million from Eli Lilly. Other
prominent names in the market are Bayer Healthcare Pharmaceuticals, Taiho Pharmaceutical, and Boehringer Ingelheim.
Browse the full Global Colorectal Cancer Therapeutics Market report at http://www.mrrse.com/colorectal-cancer-therapeutics